Elena Moreno-Olmedo: Glad to share our 10-year results at ASTRO 2023.

Quoting Elena Moreno-Olmedo, RadioOncology Clinical Research Fellow at University of Oxford, on X/Twitter:

“Glad to share our 10y results at ASTRO 2023.
Looking for the biological benefit of ultra hypo fractionation, safety and comfort of the patient and cost-effectiveness of the process, this prospective study was initiated in 2010.

1st endpoints: validation inmobilization system and dose schedule.
2nd: potential predictive risk factors and relationship PSA nadir and survival.
120 pts. LR+IR. 101 GS 6. 90% cT1c-T2a (mpMRI).
US-guided transperineal implant, rigid catheters, sutured fixed template.

Toxicity profile:

Uni and multivariate analysis found significant factors, associated with/ any grade of acute GU tox: IPSS, prostate vol, V100, V150, V200, and D10% urethra.

10y survival outcomes below.

Future directions? Let’s extrapolate to SABR.”

For more information click here.
Source: Elena Moreno-Olmedo/Twitter.